Skip to main content
DCOY logo

Decoy Therapeutics Inc. (DCOY) Stock Price & Analysis

Decoy Therapeutics Inc. (DCOY) — MoonshotScore 18/100 (Weak band), calculated Nov 18, 2026. Price $0.8701 (-1.12%), as of the Nov 19, 2026 trading session.

Educational signal · not a buy or sell recommendation · How to read this

$0.8701 −$0.0099 (-1.12%)

Decoy Therapeutics Inc. · DCOY

Decoy Therapeutics Inc. is an early-stage biotechnology firm based in Cambridge, Massachusetts, leveraging AI and machine learning to develop novel peptide conjugate drug candidates for unmet medical needs. The company focuses on oncology, utilizing its proprietary Decoy Receptor platform to engineer proteins that redirect immune responses.

Price as of Nov 19, 2026

Key Statistics

18 of 100

MoonshotScore v2 · Decoy Therapeutics (DCOY)

Weak
Business Quality Poor (6)
Financial Safety Strained (35)
Valuation Fair (68)
Growth Durability Shrinking (9)
Momentum Falling (15)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality, a strained balance sheet and stalling growth — broad distress, a capital-preservation call, not a value entry. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Strained; Valuation: Fair; Growth Durability: Shrinking; Momentum: Falling.

  • EPS beat 5 of the last 8 reports
  • Altman Z -21.79 · Piotroski F 3

Holding back: weak fundamentals, soft growth, weak price trend

Helping: an attractive price

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for DCOY (57 recorded, newest six shown)
RecordedScoreBand
28Weak
29Weak
22Weak
22Weak
18Weak
18Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

As of
MeasureValue
Latest provided price$0.8701
Change on the day-1.12%
52-week range$0.8701 – $16.92
Shares traded on the day105.4K

Price & events

Other perspectives

Council score for Decoy Therapeutics (DCOY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Negative
Financial Safety Weak
Valuation Moderate
Growth Durability Negative
Momentum Negative

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Neutral read

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Strong
ROE Negative
Gross Margin Negative

Read on: Jun 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Jun 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Decoy Therapeutics (DCOY), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Decoy Therapeutics Inc. (DCOY) is the company analyzed here. It employs 11 people and is led by Frederick E. Pierce.

2 · Latest results

What do the latest results show for Decoy Therapeutics (DCOY)?

Short answer · as of

Against analyst estimates the company has EPS beat 5 of the last 8 reports.

3 · Financial strengths and risks

What are the financial strengths and risks for Decoy Therapeutics (DCOY)?

Short answer · as of

The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is weak fundamentals, soft growth, weak price trend. The distress and quality screens read Altman Z -21.79 · Piotroski F 3. Trailing ratios: current ratio 1.83.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -21.79 sits in the distress zone (elevated bankruptcy risk).
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Decoy Therapeutics (DCOY)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $11.88M · EPS -11.34 · 1 analysts.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • No quarterly income statement is held for DCOY.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Decoy Therapeutics compare with its peers?

Short answer

Decoy Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Exelixis, Inc. (EXEL) Same industry, near in market value$65.83 Nov 19, 2026$16.1B98 5-pillar Nov 18, 2026
United Therapeutics Corporation (UTHR) Same industry, near in market value$577.34 Nov 18, 2026$24.6B97 5-pillar Nov 18, 2026
argenx SE (ARGX) Same industry, near in market value$942.04 Nov 19, 2026$59.2B96 5-pillar Nov 18, 2026
Ascendis Pharma A/S (ASND) Same industry, near in market value$255.96 Nov 19, 2026$16.8B96 5-pillar Nov 18, 2026
Regeneron Pharmaceuticals, Inc. (REGN) Same industry, near in market value$945.53 Nov 18, 2026$97.8B95 5-pillar Nov 18, 2026
Neurocrine Biosciences, Inc. (NBIX) Same industry, near in market value$162.86 Nov 18, 2026$16.5B95 5-pillar Nov 18, 2026
Halozyme Therapeutics, Inc. (HALO) Same industry, near in market value$93.04 Nov 19, 2026$10.6B95 5-pillar Nov 18, 2026
Bio-Techne Corporation (TECH) Same industry, near in market value$72.70 Nov 19, 2026$11.4B92 5-pillar Nov 18, 2026
Incyte Corporation (INCY) Same industry, near in market value$117.80 Nov 18, 2026$24.0B91 5-pillar Nov 18, 2026
Vertex Pharmaceuticals Incorporated (VRTX) Same industry, near in market value$536.45 Nov 18, 2026$136B90 5-pillar Nov 18, 2026
TG Therapeutics, Inc. (TGTX) Same industry, near in market value$64.88 Nov 19, 2026$9.81B90 5-pillar Nov 18, 2026
Novo Nordisk A/S (NVO) Same industry, near in market value$39.43 Nov 18, 2026$174B87 5-pillar Nov 18, 2026
Decoy Therapeutics (DCOY) — this page$0.8701—18

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Revenue estimate
$11.88M
EPS estimate
$-11.34

Measured against a quoted price of $0.8701 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Aug 31, 2026

Transactions
10
Identified insiders
10
Purchases
0
Sales
0
Other transactions
10

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held DCOY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported DCOY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Decoy Therapeutics (DCOY)?

Read these with our analysis →

What Investors Ask About Decoy Therapeutics (DCOY)

These answers are editorial: 1 of these 9 answers is drawn from the DCOY research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for DCOY?

DCOY carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is DCOY a good stock to buy?

Stock Expert AI does not rate DCOY buy, sell or hold. Decoy Therapeutics Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the DCOY stock price today?

The last price recorded for Decoy Therapeutics Inc. (DCOY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for DCOY?

As an early-stage biotechnology company, Decoy Therapeutics Inc. faces several significant risks. A primary concern is the inherently high attrition rate associated with drug development; most drug candidates fail during preclinical or clinical trials, leading to substantial financial losses.

What are the key factors to evaluate for DCOY?

Decoy Therapeutics Inc. (DCOY) holds a MoonshotScore in the low range. Early-stage biotechnology firm focused on developing novel drug candidates for unmet medical needs. Not financial advice.

How frequently does DCOY data refresh on this page?

DCOY's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven DCOY's recent stock price performance?

Decoy Therapeutics Inc. (DCOY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Decoy Receptor platform technology for novel immunotherapies. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider DCOY overvalued or undervalued right now?

Decoy Therapeutics Inc. (DCOY) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research DCOY before investing?

Before investing in Decoy Therapeutics Inc. (DCOY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 15 figures on this page — 5 from Financial Modeling Prep (FMP), 9 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.